A phase I study of selumetinib (AZD6244/ARRY-142866), a MEK1/2 inhibitor, in combination with cetuximab in refractory solid tumors and KRAS mutant colorectal cancer

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

E. Eisenhauer, P. Therasse, Jan Bogaerts et al. · European Journal of Cancer · 2008 · 29.5K citations

Medicine, Oncology, Treatment Planning +14

<i>K-ras</i> Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer

Christos S. Karapetis, Shirin Khambata‐Ford, Derek J. Jonker et al. · New England Journal of Medicine · 2008 · 3.6K citations

Medicine, Oncology, Pharmacology +17

Wild-Type <i>BRAF</i> Is Required for Response to Panitumumab or Cetuximab in Metastatic Colorectal Cancer

Federica Di Nicolantonio, Miriam Martini, Francesca Molinari et al. · Journal of Clinical Oncology · 2008 · 1.6K citations · Full text

Medicine, Oncology, Pharmacology +17

Oncogenic Activation of the RAS/RAF Signaling Pathway Impairs the Response of Metastatic Colorectal Cancers to Anti–Epidermal Growth Factor Receptor Antibody Therapies

Silvia Benvenuti, Andrea Sartore‐Bianchi, Federica Di Nicolantonio et al. · Cancer Research · 2007 · 830 citations · Full text

Medicine, Cancer Biology, Oncology +16

Biological Characterization of ARRY-142886 (AZD6244), a Potent, Highly Selective Mitogen-Activated Protein Kinase Kinase 1/2 Inhibitor

Tammie C. Yeh, Vivienne Marsh, Bryan A. Bernat et al. · Clinical Cancer Research · 2007 · 583 citations · Full text

Medicine, Oncology, Pharmacology +14